Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe
KIRIN HLDGS CO LTD S/ADR (KNBWY)
US:NASDAQ Investor Relations:
kirinholdings.co.jp/english/ir
Company Research
Source: Business Wire
Second- and third-line treatment for adults with mycosis fungoides or Sézary syndrome reimbursed by Croatia’s National Health Insurance Fund (NHIF), effective as of 15th November 2024.Bulgaria’s Ministry of Health also confirms positive second-line reimbursement, effective 2nd January 2025. GALASHIELS & MARLOW, England & BAAR, Switzerland--(BUSINESS WIRE)--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd., and Swixx BioPharma AG today announced that the Croatian National Health Insurance Fund (NHIF) and the Bulgarian Ministry of Health have both approved the reimbursement of POTELIGEO® (mogamulizumab) for adult patients with mycosis fungoides (MF), and Sézary syndrome (SS).MF and SS are two subtypes of cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin’s lymphoma that presents and persists in the skin and can cause debilitating physical, emotional and social challenges.1 MF—the most common CTCL subtype—accounts for approximately 60% of all
Show less
Read more
Impact Snapshot
Event Time:
KNBWY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNBWY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNBWY alerts
High impacting KIRIN HLDGS CO LTD S/ADR news events
Weekly update
A roundup of the hottest topics
KNBWY
News
- Orchard Therapeutics Celebrates Addition of Metachromatic Leukodystrophy to the U.S. Recommended Uniform Screening Panel [Yahoo! Finance]Yahoo! Finance
- Kyowa Kirin (TSE:4151) Valuation Check as Shares Climb 11% Year to Date [Yahoo! Finance]Yahoo! Finance
- Kirin (OTCMKTS:KNBWY) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=KNBWY&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a>MarketBeat
- "Ethyl Alcohol and Chemicals Market Size to Hit $1.51 Trillion in 2025" [Yahoo! Finance]Yahoo! Finance
- Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman [Yahoo! Finance]Yahoo! Finance